Liraglutide: GLP-1 Agonist Research Profile
Before semaglutide became a household name, there was liraglutide. Approved by the FDA in 2010, it was the drug that proved a once-daily GLP-1 receptor agonist could lower blood sugar, reduce cardiovascular risk, and help people lose weight — all in one molecule.
Before semaglutide became a household name, there was liraglutide. Approved by the FDA in 2010, it was the drug that proved a once-daily GLP-1 receptor agonist could lower blood sugar, reduce cardiovascular risk, and help people lose weight — all in one molecule. It opened the door for everything that followed.
Now, more than fifteen years after its first approval, liraglutide occupies an unusual position. It is no longer the most potent GLP-1 drug available. Newer agents produce more weight loss and require less frequent dosing. But liraglutide has something its successors lack: a decade and a half of real-world safety data, cardiovascular outcomes evidence from the landmark LEADER trial, pediatric approvals for both diabetes and obesity, and — as of late 2024 — the first generic versions of any GLP-1 receptor agonist.
This profile covers the pharmacology, clinical evidence, safety data, and current role of liraglutide, with honest context about where it stands against newer GLP-1 agents.
Table of Contents
- Quick Facts
- What Is Liraglutide?
- Development History
- How Liraglutide Works: Mechanisms of Action
- Clinical Research
- Administration and Dosing
- Safety Profile and Side Effects
- How Liraglutide Compares to Newer GLP-1 Agents
- Legal and Regulatory Status
- Frequently Asked Questions
- The Bottom Line
Quick Facts
| Property | Detail |
|---|---|
| Generic Name | Liraglutide |
| Brand Names | Victoza (diabetes), Saxenda (weight management) |
| Type | GLP-1 receptor agonist (incretin mimetic) |
| Amino Acid Count | 31 amino acids |
| Molecular Weight | 3,751 Da |
| Molecular Formula | C₁₇₂H₂₆₅N₄₃O₅₁ |
| Homology to Native GLP-1 | 97% |
| Key Modification | C-16 palmitic acid chain at Lys26 via glutamic acid spacer; Arg34Lys substitution |
| Half-Life | ~13 hours (vs. ~2 minutes for native GLP-1) |
| Plasma Protein Binding | ~99% (reversible albumin binding) |
| Bioavailability | 55% (subcutaneous injection) |
| Route | Subcutaneous injection, once daily |
| Manufacturer | Novo Nordisk |
| First FDA Approval | January 25, 2010 (Victoza, type 2 diabetes) |
| Weight Management Approval | December 2014 (Saxenda, obesity) |
| Pediatric Approvals | 2019 (Victoza, T2D age ≥10); 2020 (Saxenda, obesity age 12–17) |
| First Generic Approved | December 2024 (Hikma Pharmaceuticals) |
What Is Liraglutide?
Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), an incretin hormone produced by L-cells in the small intestine after eating. Natural GLP-1 stimulates insulin release in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and signals satiety to the brain. The problem is that native GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) within about two minutes of entering circulation — far too fast to be useful as a drug.
Liraglutide solves this through structural engineering. Compared to native GLP-1(7-37), it differs at a single amino acid position (arginine replaces lysine at position 34) and carries a 16-carbon palmitic acid chain attached to lysine at position 26 via a glutamic acid spacer. This fatty acid "tail" provides three mechanisms of extended duration: it promotes self-association at the injection site (slowing absorption), enables reversible binding to serum albumin in the bloodstream (shielding the peptide from enzymatic breakdown and renal clearance), and confers resistance to DPP-4 degradation.
The result is a half-life of approximately 13 hours. After subcutaneous injection, roughly 99% of circulating liraglutide is bound to albumin at any given time, with only 1–2% circulating as free peptide available to activate GLP-1 receptors. The combined size of the peptide-albumin complex exceeds the kidney's filtration threshold, preventing rapid renal elimination. Liraglutide is produced by recombinant DNA technology in Saccharomyces cerevisiae (baker's yeast) and delivered as a pre-filled injection pen.
Development History
The GLP-1 field began in the mid-1980s, when researchers identified the hormone as a potent insulin secretagogue. By 1987, GLP-1 infusion could normalize blood glucose in people with type 2 diabetes. But the two-minute half-life made continuous infusion impractical.
Novo Nordisk entered the space in 1991. Scientist Lotte Bjerre Knudsen joined the GLP-1 project and led drug discovery for what became liraglutide. The team's critical insight came from insulin: Novo Nordisk had developed insulin detemir, a long-acting insulin using a C-14 fatty acid chain for albumin binding. The same principle could work for GLP-1, but early attempts with C-8 fatty acids had weak binding and instability.
By 1997, Knudsen's team found the optimal configuration — a C-16 palmitic acid chain at position 26 — that balanced strong enough albumin binding for once-daily duration against the need for free peptide to reach GLP-1 receptors. Longer fatty acids improved albumin affinity but shrank the active free fraction. Liraglutide hit the sweet spot. This acylation platform became the foundation for semaglutide, which uses the same albumin-binding strategy with further optimizations for once-weekly dosing.
Key regulatory milestones:
- 2009: EMA approves Victoza for type 2 diabetes
- January 2010: FDA approves Victoza (1.2 mg, 1.8 mg) for adult type 2 diabetes
- December 2014: FDA approves Saxenda (3.0 mg) for chronic weight management
- June 2019: FDA expands Victoza to children ≥10 with type 2 diabetes — the first non-insulin drug for pediatric T2D since metformin
- December 2020: FDA approves Saxenda for adolescent obesity (ages 12–17)
- December 2024: First generic liraglutide approved (Hikma Pharmaceuticals)
How Liraglutide Works: Mechanisms of Action
Liraglutide activates the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed in the pancreas, brain, heart, kidneys, and GI tract. Its effects work through four coordinated actions.
Glucose-dependent insulin secretion. Liraglutide binding to GLP-1R on pancreatic beta cells increases intracellular cyclic AMP (cAMP), potentiating glucose-stimulated insulin release. It amplifies insulin secretion only when blood sugar is elevated, substantially lowering hypoglycemia risk compared to sulfonylureas. Liraglutide also suppresses glucagon secretion from alpha cells, reducing hepatic glucose production. This dual effect explains HbA1c reductions of 1.0–1.5% in clinical trials.
Appetite and satiety regulation. GLP-1 receptors in the hypothalamus and brainstem mediate central appetite suppression. Liraglutide reduces hunger and increases fullness, decreasing caloric intake by about 16% versus placebo. This is the primary driver of weight loss — though the caloric reduction is notably smaller than with semaglutide (~35%), which partly explains the weight loss gap between the two drugs.
Gastric emptying. Liraglutide slows stomach emptying, contributing to both satiety and reduced postprandial glucose spikes. This effect is most pronounced early in treatment and may diminish with chronic use.
Beta-cell preservation. Preclinical data show that liraglutide promotes beta-cell proliferation and inhibits apoptosis. In humans, it improved markers of beta-cell function including HOMA-B and proinsulin-to-insulin ratios. Whether this translates into durable disease modification remains under investigation.
Clinical Research
Liraglutide has one of the most extensive clinical trial programs of any peptide therapeutic. Three major programs define its evidence base.
The LEAD Program: Type 2 Diabetes
The LEAD (Liraglutide Effect and Action in Diabetes) program ran six Phase 3 trials testing liraglutide as monotherapy and in combination with metformin, sulfonylureas, thiazolidinediones, and insulin. Unusually, LEAD included active comparators rather than relying solely on placebo.
LEAD-2 (Nauck et al., 2009): 1,091 patients randomized to liraglutide, placebo, or glimepiride, all added to metformin. At 26 weeks, liraglutide 1.2 mg and 1.8 mg matched glimepiride for HbA1c reduction (1.0%) but with weight loss of 2.6–2.8 kg instead of weight gain, and far fewer hypoglycemic episodes.
LEAD-6 compared liraglutide 1.8 mg directly to exenatide twice daily. Liraglutide produced greater HbA1c reductions (−1.12% vs. −0.79%) and better patient satisfaction scores.
Across the full program, liraglutide consistently delivered HbA1c reductions of 1.0–1.5%, weight loss of 2–3 kg, modest blood pressure reductions, and low hypoglycemia rates.
The LEADER Trial: Cardiovascular Outcomes
The LEADER trial (Marso et al., 2016, NEJM) randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg or placebo, with a median follow-up of 3.8 years across 410 sites in 32 countries.
The primary composite outcome — cardiovascular death, nonfatal MI, or nonfatal stroke (three-point MACE) — occurred in 13.0% of the liraglutide group versus 14.9% of placebo (hazard ratio 0.87; 95% CI 0.78–0.97; P = 0.01). Cardiovascular death was lower (4.7% vs. 6.0%), and all-cause mortality dropped 15%.
LEADER placed GLP-1 receptor agonists alongside SGLT2 inhibitors and metformin as the only glucose-lowering drug classes with proven cardiovascular event reduction. The 2019 ESC/EASD guidelines subsequently recommended GLP-1 agonists as first-line therapy for patients with T2D and cardiovascular disease (Class I, Level A).
A pre-specified renal analysis also found a 22% reduction in the composite renal outcome, driven by reductions in new-onset macroalbuminuria.
The SCALE Program: Weight Management
The SCALE (Satiety and Clinical Adiposity—Liraglutide Evidence) program tested liraglutide 3.0 mg for chronic weight management.
SCALE Obesity and Prediabetes (Pi-Sunyer et al., 2015, NEJM): 3,731 adults without diabetes randomized 2:1 to liraglutide or placebo for 56 weeks. Mean weight loss was 8.0% with liraglutide versus 2.6% with placebo. 63.2% lost ≥5% body weight (vs. 27.1%), and 33.1% lost ≥10% (vs. 10.6%). Liraglutide also reduced waist circumference, blood pressure, and cardiometabolic risk factors.
SCALE Diabetes (Davies et al., 2015, JAMA): In patients with T2D, weight loss was 6.0% with liraglutide 3.0 mg versus 2.0% with placebo.
SCALE Insulin (Garvey et al., 2020): The first trial of an approved anti-obesity drug in people on basal insulin. Liraglutide produced 4.3% more weight loss than placebo, with 51.8% achieving ≥5% weight loss.
Pediatric Data
The SCALE Teens trial (Kelly et al., 2020, NEJM) randomized 251 adolescents aged 12–17 with obesity to liraglutide 3.0 mg or placebo. A BMI reduction of ≥5% was seen in 43.3% of the liraglutide group versus 18.7% with placebo, and ≥10% BMI reduction in 26.1% versus 8.1%. BMI increased again after treatment stopped, underscoring that effects depend on continued use. The SCALE Kids trial has since extended the evidence to children aged 6–11.
Emerging Research
Alzheimer's disease: The ELAD trial (Edison et al., Nature Medicine) randomized 204 patients with mild-to-moderate Alzheimer's (without diabetes) to liraglutide or placebo for 52 weeks. The primary endpoint (cerebral glucose metabolism) was not met, but secondary analyses showed slower cognitive decline and approximately 50% less brain volume loss in multiple regions. A pooled analysis of 15,820 patients treated with liraglutide or semaglutide found a significantly lower hazard ratio (0.47) for dementia diagnosis. Larger trials are underway, including the EVOKE studies testing semaglutide in early Alzheimer's.
NASH: The LEAN trial (Armstrong et al., 2016, Lancet) found NASH resolution in 39% of liraglutide patients versus 9% of placebo, with 33% liver fat reduction in T2D patients with NAFLD.
Administration and Dosing
Liraglutide is a once-daily subcutaneous injection administered into the abdomen, thigh, or upper arm at any time of day, independent of meals. Injection sites should be rotated.
Victoza (Type 2 Diabetes)
| Week | Daily Dose | Notes |
|---|---|---|
| 1 | 0.6 mg | Starting dose only (not therapeutic) |
| 2+ | 1.2 mg | Standard maintenance |
| If needed | 1.8 mg | Maximum; increase after ≥1 week at 1.2 mg |
Saxenda (Weight Management)
| Week | Daily Dose |
|---|---|
| 1 | 0.6 mg |
| 2 | 1.2 mg |
| 3 | 1.8 mg |
| 4 | 2.4 mg |
| 5+ | 3.0 mg (maintenance) |
The five-week escalation minimizes GI side effects. For adults, response should be evaluated at 16 weeks: if less than 4% of body weight has been lost, discontinuation is recommended. For adolescents, BMI should drop at least 1% after 12 weeks on maintenance dose. If treatment is interrupted for more than 3 days, restart at 0.6 mg and repeat the titration.
Saxenda and Victoza cannot be used together — they contain the same active ingredient.
Safety Profile and Side Effects
Liraglutide's safety profile draws on more data than any other GLP-1 receptor agonist: 15+ years of clinical use, the 9,340-patient LEADER trial, the 3,731-patient SCALE trial, and extensive post-marketing surveillance.
Common Side Effects
GI symptoms are the most frequent adverse effects. In SCALE Obesity and Prediabetes: nausea (39.3% vs. 13.8% placebo), diarrhea (20.9% vs. 9.9%), constipation (19.4% vs. 8.5%), vomiting (15.7% vs. 4.1%). These are typically most intense during dose titration and diminish over weeks. Most patients who tolerate the first 4–6 weeks continue without significant GI issues.
Serious Safety Considerations
Thyroid C-cell tumors (boxed warning). Liraglutide carries an FDA boxed warning based on rodent studies showing dose-dependent increases in medullary thyroid carcinoma (MTC). However, this C-cell proliferation has not been seen in primates, and human thyroid C-cells express far fewer GLP-1 receptors. A Novo Nordisk analysis of 93 trials (101,732 participants, 207,045 patient-years) found no signal linking the drugs to thyroid cancer. Post-marketing surveillance shows a rate of 0.001 cases per 100 patient-years. The EMA concluded in 2023 that no causal relationship exists. Liraglutide remains contraindicated in patients with personal or family history of MTC or MEN 2 — a reasonable precaution for a cancer affecting roughly 1 in 30,000 adults.
Pancreatitis. Acute pancreatitis has been reported, though incidence in LEADER was similar between groups. GLP-1 agonists can raise amylase and lipase levels without indicating pancreatitis. Monitoring for symptoms (severe abdominal pain radiating to the back) is standard.
Gallbladder events. Slightly higher cholecystitis rates were seen in LEADER — a class effect likely related to altered gallbladder motility.
Hypoglycemia. Low risk when used alone or with metformin due to the glucose-dependent mechanism. Risk increases with sulfonylureas or insulin.
Fifteen years of post-marketing data from millions of patients have not revealed unexpected safety signals beyond those identified in trials. This track record is an advantage that newer agents like tirzepatide and retatrutide cannot yet match.
How Liraglutide Compares to Newer GLP-1 Agents
The STEP 8 trial (Rubino et al., 2022, JAMA) provides the most direct comparison: 338 adults randomized to semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily for 68 weeks.
| Outcome | Semaglutide 2.4 mg | Liraglutide 3.0 mg |
|---|---|---|
| Mean weight loss | 15.8% | 6.4% |
| ≥10% weight loss | 70.9% | 25.6% |
| ≥20% weight loss | 38.5% | 6.0% |
Semaglutide produced roughly 2.5 times more weight loss. Tirzepatide produces even more (up to 20.9% in SURMOUNT-1). Investigational agents like retatrutide and survodutide report higher numbers still. Liraglutide also requires daily injections versus weekly for semaglutide and dulaglutide, with oral options like orforglipron in development.
Where liraglutide retains value:
- Safety track record: 15+ years of data and the 3.8-year LEADER trial provide long-term confidence newer agents lack
- Cardiovascular evidence: LEADER demonstrated cardiovascular mortality reduction; tirzepatide's CV outcomes trial is still underway
- Generic availability: The only generic GLP-1 agonist as of late 2024. Generic semaglutide is not expected before 2030
- Pediatric approvals: FDA-approved for both pediatric diabetes (age ≥10) and adolescent obesity (age 12–17) with published NEJM data
- Cost: A cost-effectiveness analysis found semaglutide produces more weight loss per dollar spent, but generic liraglutide pricing may shift that calculus for cost-constrained patients and health systems
Legal and Regulatory Status
Liraglutide is FDA-approved under two brand names: Victoza (1.2–1.8 mg for type 2 diabetes and cardiovascular risk reduction) and Saxenda (3.0 mg for chronic weight management). It is a prescription-only medication, not a controlled substance.
Generic versions from Hikma and Teva became available in late 2024–2025, marking the first generic GLP-1 receptor agonists on the US market. The EMA approves both formulations with similar indications, though the European label does not include the MTC contraindication. Liraglutide is approved in over 90 countries and is not prohibited by WADA, though some sports organizations are discussing GLP-1 agonist regulation in weight-class sports.
Frequently Asked Questions
What is the difference between Victoza and Saxenda?
Both contain liraglutide. Victoza is dosed at 1.2–1.8 mg daily for type 2 diabetes. Saxenda is dosed at 3.0 mg daily for weight management. They cannot be used together. Victoza also carries an indication for cardiovascular risk reduction in adults with T2D and heart disease.
How much weight can I expect to lose on liraglutide?
In the SCALE trial, average weight loss was 8.0% (about 8.4 kg) over 56 weeks. About one-third lost 10% or more. About 37% did not reach the 5% threshold. Prescribers evaluate response at 16 weeks: if at least 4% of body weight has not been lost, the drug is unlikely to work with continued use.
Is liraglutide safer than semaglutide or tirzepatide?
The safety profiles are broadly similar across GLP-1 agonists — the same GI side effects, thyroid boxed warning, and pancreatitis monitoring. What liraglutide offers is the longest track record: 15 years of post-marketing data and the LEADER trial's 3.8-year follow-up give clinicians more long-term information than is available for semaglutide (marketed since 2017) or tirzepatide (marketed since 2022).
Does liraglutide have cardiovascular benefits?
Yes. LEADER demonstrated a 13% reduction in major adverse cardiovascular events and a 22% reduction in cardiovascular mortality in patients with T2D at high cardiovascular risk. These results drove guideline recommendations for GLP-1 agonists as preferred therapy in T2D patients with cardiovascular disease.
Can liraglutide be used for non-diabetic weight loss?
Yes. Saxenda (3.0 mg) is FDA-approved for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. It is also approved for adolescents aged 12–17 with obesity.
Is there a generic version of liraglutide?
Yes. The FDA approved the first generic liraglutide in December 2024 (Hikma Pharmaceuticals), and Teva has launched generics for both the diabetes and weight management indications. These are the first generic GLP-1 receptor agonists in the United States. Generic semaglutide is not expected until approximately 2030.
What happens when you stop taking liraglutide?
Weight regain is common. In the SCALE Teens trial, BMI increased during the follow-up period after stopping. The biological drivers of weight gain resume when the drug is removed. Most experts now recommend ongoing treatment for responders, similar to long-term blood pressure medications.
The Bottom Line
Liraglutide validated an entire drug class. Before its approval, GLP-1 receptor agonists were a concept; after LEAD and LEADER, they were a proven strategy for type 2 diabetes, cardiovascular protection, and weight management. Every GLP-1 drug that followed — semaglutide, tirzepatide, dulaglutide, the investigational agents retatrutide, survodutide, orforglipron, CagriSema, and pemvidutide — stands on the foundation liraglutide built.
It is no longer the most potent option. Semaglutide produces 2.5 times more weight loss. Tirzepatide produces even more. Weekly dosing is more convenient. Liraglutide's prescribing share has dropped from dominating the weight management space to less than 12% by 2023.
But potency is not the only metric that matters. Liraglutide has 15 years of safety data, the LEADER trial with nearly 10,000 patients followed for almost four years, pediatric approvals backed by NEJM trials, and generic availability. The scientific story is also far from over — the ELAD trial's brain volume findings in Alzheimer's, the LEAN trial's NASH data, and emerging work on alcohol use disorder suggest therapeutic applications well beyond current labels.
For patients and clinicians today, liraglutide fits best when a well-characterized safety profile is the priority, when generic pricing matters, when moderate weight loss is the goal, or when pediatric data is needed. For maximal weight loss, newer agents are the better choice. The right drug depends on the individual patient, their goals, their risk factors, and their access to care.
This article is for educational purposes only. PeptideJournal.org does not sell peptides, provide medical advice, or recommend the use of any substance. Always consult a qualified healthcare provider before making decisions about your health.
References
- Marso SP, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." N Engl J Med. 2016;375:311-22. NEJM
- Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." N Engl J Med. 2015;373:11-22. NEJM
- Kelly AS, et al. "A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity." N Engl J Med. 2020;382:2117-28. NEJM
- Nauck MA, et al. "Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD-2 study." Diabetes Care. 2009;32:84-90. PubMed
- Davies MJ, et al. "Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial." JAMA. 2015;314:687-99. JAMA
- Rubino DM, et al. "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial." JAMA. 2022;327:138-50. JAMA
- Mann JFE, et al. "Liraglutide and Renal Outcomes in Type 2 Diabetes." N Engl J Med. 2017;377:839-48. NEJM
- Armstrong MJ, et al. "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN)." Lancet. 2016;387:679-90. Lancet
- Edison P, et al. "Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial." Nat Med. 2025. Nature Medicine
- Knudsen LB, Lau J. "The Discovery and Development of Liraglutide and Semaglutide." Front Endocrinol. 2019;10:155. PMC
- Nauck MA. "The design of the liraglutide clinical trial programme." Diabetes Obes Metab. 2012;14(Suppl 2):4-12. Wiley
- Garvey WT, et al. "Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial." Diabetes Care. 2020;43:1085-93. PMC
- Vilsbøll T, et al. "Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use." Diabetes Obes Metab. 2026. Wiley
- Cerillo JL, Parmar M. "Liraglutide." StatPearls. Updated October 6, 2024. NCBI Bookshelf
- Azuri J, et al. "Liraglutide versus semaglutide for weight reduction — a cost needed to treat analysis." Obesity. 2023;31:1510-12. PubMed
- Knudsen LB. "Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity." ACS Pharmacol Transl Sci. 2019;2:468-84. ACS